2025-09-23 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the provided data, formatted as requested.

## Johnson & Johnson (JNJ) Stock Analysis

Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer health products.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 29.62%
*   **VOO Cumulative Return:** 106.97%
*   **Return Disparity:** -76.8
*   **Relative Disparity:** 6.0 (Indicates JNJ's underperformance is in the lower range of its historical relative performance compared to VOO)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the covered period. The relative disparity suggests this underperformance is near the lower end of its historical range, implying the situation could potentially improve, or that this underperformance is becoming the new normal.

### Alpha, Beta Analysis:

| Year       | CAGR    | MDD     | Alpha   | Beta | Cap(B) |
|------------|---------|---------|---------|------|--------|
| 2015-2017  | 28.0%   | 56.1%   | -1.0%   | -0.0 | 336.5  |
| 2016-2018  | 8.0%    | 56.6%   | -10.0%  | 0.0  | 310.8  |
| 2017-2019  | 18.0%   | 56.6%   | -12.0%  | 0.7  | 351.3  |
| 2018-2020  | 12.0%   | 59.2%   | -8.0%   | 0.3  | 379.0  |
| 2019-2021  | 32.0%   | 59.6%   | -16.0%  | 0.2  | 412.0  |
| 2020-2022  | 7.0%    | 61.4%   | 5.0%    | 0.2  | 425.4  |
| 2021-2023  | -15.0%  | 61.4%   | -33.0%  | 0.4  | 377.5  |
| 2022-2024  | -35.0%  | 61.4%   | -61.0%  | 0.3  | 348.3  |
| 2023-2025  | 2.0%    | 70.1%   | -56.0%  | 0.2  | 424.3  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  The CAGR has fluctuated significantly, with negative values in recent periods (2021-2025), indicating a period of weak or negative growth.
*   **MDD (Maximum Drawdown):**  MDD is consistently high, showing significant potential for loss from peak to trough.  It has increased significantly in recent years.
*   **Alpha:** Alpha is consistently negative, indicating underperformance relative to the benchmark, particularly in recent years.
*   **Beta:** Beta is low, suggesting that the stock is less volatile than the overall market.
*   **Cap(B):** Market Cap has been variable, reflecting the company's changing valuation over time.

### 2. Recent Price Action

*   **Current Price:** 176.19
*   **Last Market Data:** Price: 174.21, Previous Close: 176.19, Change: -1.12
*   **5-day Moving Average:** 176.28
*   **20-day Moving Average:** 177.23
*   **60-day Moving Average:** 169.48

**Analysis:** The stock is trading below its 5-day and 20-day moving averages, suggesting a short-term downtrend.  However, the price is above the 60-day moving average, indicating a longer-term uptrend.  The recent price drop of -1.12 suggests some negative pressure.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 46.85 (Neutral)
*   **PPO:** -0.4034 (Slightly Bearish)
*   **Hybrid Signal:** Sell 0.7% of holdings (2 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Disparity Change:** -2.4 (Short-term decline)
*   **Expected Return:** -529.0% (Significantly Negative)

**Analysis:** The MRI suggests a low-risk environment for the market. The RSI is neutral, indicating neither overbought nor oversold conditions. The negative PPO hints at a possible downtrend, while the Hybrid Signal recommends selling a small portion of holdings, suggesting caution.  The significantly negative expected return is a major concern, implying a potential for substantial underperformance compared to the S&P 500 over the long term. The recent price drop in the last market session further reinforces the short-term downward pressure.

### 4. Recent News & Significant Events

*   **Kenvue Stock Hits All-Time Low:**  Negative news impacting a subsidiary can indirectly affect the parent company's sentiment.
*   **J&J Launches Shockwave Javelin in Europe:** Positive news about product expansion and innovation.
*   **Analyst Report: Kenvue Inc.:** Keep monitoring it.
*   **Tylenol-maker Kenvue Faces Scrutiny Over Autism Claims:** This is a significant negative development that could impact sales and reputation.
*   **What is Kenvue? The Tylenol maker facing RFK Jr. scrutiny over autism claims:** This is a significant negative development that could impact sales and reputation.
*   **J&J Adds $63B in Market Cap in 3 Months:** Positive news suggesting a strong recovery or growth phase.

**Analysis:** The news is mixed.  The positive news about market cap growth and product launches is counteracted by concerns surrounding Kenvue and potential legal issues related to Tylenol.  The negative news surrounding Kenvue, particularly the all-time low stock price and scrutiny over autism claims, is a significant risk factor.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 2.17)
*   **Opinions:** 23
*   **Target Price (avg/high/low):** 179.64 / 206.00 / 155.00

**Analysis:** Analyst sentiment is generally positive, with a consensus "Buy" rating. However, the wide range in target prices indicates some uncertainty about the stock's future performance.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2024-07-25 | 1.95 | 22.45 B$   |
| 2025-07-24 | 1.95 | 22.45 B$   |

**Analysis:**  Earnings per share (EPS) and revenue have been inconsistent. The most recent EPS of 2.3 and revenue of $23.74B show the latest performance. Monitoring these numbers in the coming quarters is essential to evaluate the company's earnings potential.

### 6. Financial Information

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $23.74B   | 67.87%        |
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |
| 2024-06-30   | $22.45B   | 69.40%        |

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $78.47B   | 7.06%    |
| 2025-03-31   | $78.11B   | 14.08%   |
| 2024-12-31   | $71.49B   | 4.80%    |
| 2024-09-30   | $70.16B   | 3.84%    |
| 2024-06-30   | $71.54B   | 6.55%    |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable over the past few quarters, with a slight increase in the most recent quarter.
*   **Profit Margin:** Profit margins remain strong, consistently above 66%.
*   **Equity:** Equity has been increasing.
*   **ROE (Return on Equity):** ROE has fluctuated, indicating variability in the company's ability to generate profits from shareholder equity.

### 7. Overall Analysis & Summary

Johnson & Johnson (JNJ) presents a mixed picture.

*   **Underperformance:**  The most significant concern is the substantial underperformance compared to the S&P 500 and the significantly negative expected return.
*   **Mixed Signals:**  Technical indicators are providing mixed signals, with short-term downward pressure and longer-term uptrend indications.
*   **Analyst Sentiment:** Analyst opinions remain positive, but recent news events, particularly those surrounding Kenvue, introduce significant risk.
*   **Financial Health:** The company maintains a strong financial position with healthy profit margins, but ROE variability is a concern.
*   **Recommendation:** Given the underperformance, negative expected return, and negative news surrounding Kenvue, a cautious approach is warranted. The hybrid signal is sell, and the negative PPO confirms a downtrend. It is also below the 5 and 20 day moving averages, again confirming a downtrend.
